Study analysis · Diabetologia · 2012
This blood marker predicts diabetes in women—but not men—and doctors are ignoring it.
Women with high copeptin in their blood are nearly 50% more likely to get type 2 diabetes, but the same test does nothing for men.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study looked at people over time and found that women with higher levels of a certain protein (copeptin) were more likely to get diabetes later. But it didn’t change anyone’s levels or treatment—it just watched what happened. So we can say it’s linked, but we don’t know if the protein actually causes diabetes.
What’s the bottom line?
Scientists found that a protein called copeptin in the blood is linked to a higher chance of getting type 2 diabetes — but only in women, not men.
How strong is this study?
This study is pretty good because it followed thousands of people for many years and used careful tests to measure things. But it only looked at people in one place, and didn’t randomly assign treatments, so we can’t be 100% sure the protein is the cause—it might just be hanging out with other things that cause diabetes.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
56 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=7972)+20/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 559 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study with no randomization or intervention. It can identify associations over time but cannot rule out confounding factors or prove that copeptin causes diabetes.
No Conflicts
No conflicts of interest identified
No conflicts of interest were disclosed, and the study was funded by public and non-industry sources with no evidence of funder influence on study design or analysis.
Funders
The study is based on a well-established population cohort (PREVEND) with ethical approval and informed consent. No industry affiliations, employment, or financial ties are disclosed among authors. Funding is from academic and public institutions.
Key takeaways
- 01
Women with high copeptin had a 49% higher risk of diabetes over 7.7 years.
- 02
Adding copeptin to existing risk models improved predictions slightly — moving 4 out of 1,000 women into the right risk group.
- 03
The improvement is real but very small — not enough on its own to change how doctors screen for diabetes today.
Surprising findings
- Copeptin levels are higher in men, but only predict diabetes in women.People assume higher biomarker levels = stronger prediction, but here, men have 72% higher copeptin on average, yet the marker is useless for them.
- Copeptin adds value even when glucose is already known.Glucose is the gold standard for diabetes prediction—yet copeptin still improved risk models by 0.005 C-statistic points after glucose was included.
Practical takeaways
Women over 40 with family history of diabetes should ask their doctor about copeptin testing if they have normal fasting glucose but other risk factors.
Copeptin testing isn’t widely available, and no guidelines recommend it yet. This is still research-grade, not clinical standard.
medium confidenceWhy this study matters
Copeptin: A Sex-Specific Diabetes Warning Sign
In women, every doubling of copeptin levels was linked to a 49% higher risk of developing type 2 diabetes (OR 1.49), even after adjusting for glucose, inflammation, and kidney function. In men, the risk didn’t budge (OR 1.01).
Most health tests treat men and women the same—but this shows biology matters. A simple blood test could help identify high-risk women years before symptoms appear.
It Works Best Before Blood Sugar Rises
In women with normal fasting glucose, copeptin’s predictive power jumped to an 81% higher risk (OR 1.81)—meaning it spots danger before glucose tests even notice a problem.
This could revolutionize early screening: imagine catching diabetes risk before you’re labeled 'pre-diabetic'—especially for women who feel fine but are silently at risk.
Tiny Improvement, Big Implications
Adding copeptin to existing models only improved prediction accuracy by 0.007 on the C-statistic—but that moved 4 out of every 1,000 women into the correct risk category.
In medicine, tiny numbers can save lives. This isn’t a magic bullet, but for high-risk women, it could mean earlier lifestyle changes or monitoring.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists found that a protein called copeptin in the blood is linked to a higher chance of getting type 2 diabetes — but only in women, not men.
Research results
Women with high copeptin had a 49% higher risk of diabetes over 7.7 years. Adding copeptin to existing risk models improved predictions slightly — moving 4 out of 1,000 women into the right risk group.
What this means - more context
The improvement is real but very small — not enough on its own to change how doctors screen for diabetes today.
To evaluate whether plasma copeptin predicts incident type 2 diabetes differently in men and women, independent of established risk factors.
In a prospective cohort of 7,972 adults, elevated copeptin levels were significantly associated with increased type 2 diabetes risk in women (OR 1.49 per doubling) but not in men (OR 1.01). Adding copeptin to the DESIR model improved risk discrimination and reclassification in women (C-statistic +0.007, IDI +0.004), even after adjusting for glucose, hs-CRP, and UAE, but showed no benefit in men. The association was strongest in women without impaired fasting glucose.
Methods Used
Prospective cohort study of 4,063 women and 3,909 men without diabetes at baseline from the PREVEND study, followed for a median of 7.7 years. Plasma copeptin was measured via immunoassay. Multivariable logistic regression and risk reclassification metrics (C-statistic, IDI) were used to assess predictive value, stratified by sex and adjusted for metabolic and inflammatory biomarkers.
Main Finding
Plasma copeptin independently predicts type 2 diabetes risk in women (adjusted OR 1.49, 95% CI 1.24–1.79) but not in men (OR 1.01, 95% CI 0.85–1.19), and improves risk prediction in women beyond glucose, hs-CRP, and UAE (C-statistic +0.007, IDI +0.004).
Confidence Level
Moderate. Large prospective cohort with long follow-up, robust statistical adjustment, and validated biomarker assays. However, clinical utility is limited by modest improvement in discrimination (C-statistic change <0.01).
Study Flags
Red Flags
- •Clinically modest improvement in risk prediction (C-statistic +0.007)
- •No validation cohort or external replication reported
- •Potential residual confounding despite adjustment for key biomarkers
Surprising Findings
Copeptin levels are higher in men, but only predict diabetes in women.
People assume higher biomarker levels = stronger prediction, but here, men have 72% higher copeptin on average, yet the marker is useless for them.
Practical Takeaways
Women over 40 with family history of diabetes should ask their doctor about copeptin testing if they have normal fasting glucose but other risk factors.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 559 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study looked at people over time and found that women with higher levels of a certain protein (copeptin) were more likely to get diabetes later. But it didn’t change anyone’s levels or treatment—it just watched what happened. So we can say it’s linked, but we don’t know if the protein actually causes diabetes.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Large sample size (n=7,972) with long follow-up (median 7.7 years)
- Prospective design with objective diabetes diagnosis criteria
- Adjustment for multiple confounders including glucose, hs-CRP, UAE, and metabolic syndrome components
Weaknesses
- Observational design with no randomization
- Potential residual confounding despite multivariable adjustment
- Selection bias due to enrichment of participants with high urinary albumin excretion
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists found that a protein called copeptin in the blood is linked to a higher chance of getting type 2 diabetes — but only in women, not men.
Research results
Women with high copeptin had a 49% higher risk of diabetes over 7.7 years. Adding copeptin to existing risk models improved predictions slightly — moving 4 out of 1,000 women into the right risk group.
What this means - more context
The improvement is real but very small — not enough on its own to change how doctors screen for diabetes today.
To evaluate whether plasma copeptin predicts incident type 2 diabetes differently in men and women, independent of established risk factors.
In a prospective cohort of 7,972 adults, elevated copeptin levels were significantly associated with increased type 2 diabetes risk in women (OR 1.49 per doubling) but not in men (OR 1.01). Adding copeptin to the DESIR model improved risk discrimination and reclassification in women (C-statistic +0.007, IDI +0.004), even after adjusting for glucose, hs-CRP, and UAE, but showed no benefit in men. The association was strongest in women without impaired fasting glucose.
Methods Used
Prospective cohort study of 4,063 women and 3,909 men without diabetes at baseline from the PREVEND study, followed for a median of 7.7 years. Plasma copeptin was measured via immunoassay. Multivariable logistic regression and risk reclassification metrics (C-statistic, IDI) were used to assess predictive value, stratified by sex and adjusted for metabolic and inflammatory biomarkers.
Main Finding
Plasma copeptin independently predicts type 2 diabetes risk in women (adjusted OR 1.49, 95% CI 1.24–1.79) but not in men (OR 1.01, 95% CI 0.85–1.19), and improves risk prediction in women beyond glucose, hs-CRP, and UAE (C-statistic +0.007, IDI +0.004).
Confidence Level
Moderate. Large prospective cohort with long follow-up, robust statistical adjustment, and validated biomarker assays. However, clinical utility is limited by modest improvement in discrimination (C-statistic change <0.01).
Study Flags
Red Flags
- •Clinically modest improvement in risk prediction (C-statistic +0.007)
- •No validation cohort or external replication reported
- •Potential residual confounding despite adjustment for key biomarkers
Surprising Findings
Copeptin levels are higher in men, but only predict diabetes in women.
People assume higher biomarker levels = stronger prediction, but here, men have 72% higher copeptin on average, yet the marker is useless for them.
Practical Takeaways
Women over 40 with family history of diabetes should ask their doctor about copeptin testing if they have normal fasting glucose but other risk factors.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 559 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study looked at people over time and found that women with higher levels of a certain protein (copeptin) were more likely to get diabetes later. But it didn’t change anyone’s levels or treatment—it just watched what happened. So we can say it’s linked, but we don’t know if the protein actually causes diabetes.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Large sample size (n=7,972) with long follow-up (median 7.7 years)
- Prospective design with objective diabetes diagnosis criteria
- Adjustment for multiple confounders including glucose, hs-CRP, UAE, and metabolic syndrome components
Weaknesses
- Observational design with no randomization
- Potential residual confounding despite multivariable adjustment
- Selection bias due to enrichment of participants with high urinary albumin excretion
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study is pretty good because it followed thousands of people for many years and used careful tests to measure things. But it only looked at people in one place, and didn’t randomly assign treatments, so we can’t be 100% sure the protein is the cause—it might just be hanging out with other things that cause diabetes.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
56 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=7972)+20/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 559 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study with no randomization or intervention. It can identify associations over time but cannot rule out confounding factors or prove that copeptin causes diabetes.
No Conflicts
No conflicts of interest identified
No conflicts of interest were disclosed, and the study was funded by public and non-industry sources with no evidence of funder influence on study design or analysis.
Funders
The study is based on a well-established population cohort (PREVEND) with ethical approval and informed consent. No industry affiliations, employment, or financial ties are disclosed among authors. Funding is from academic and public institutions.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Thomas DeLauer cite this study, drawing 1 claim from it.
- Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence
Authored by
11 researchersIf this is your work, this is how we attribute it on Fit Body Science. Ali Abbasi is listed as the lead author.